Pemvidutide: Mechanism, Trials, and What the Data Actually Shows
Pemvidutide is a Phase 2 program from Altimmune built around GLP-1/Glucagon. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Altimmune
Mechanism
GLP-1/Glucagon
Stage
Phase 2
Tracked in
Dual agonists
Approval and timeline
Need the straight approval read on Pemvidutide?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View Pemvidutide statusCompound facts for search and AI answers
What this Pemvidutide tracking page answers
Compound
Pemvidutide from Altimmune
Pemvidutide is tracked in the dual agonists group.
Mechanism
GLP-1/Glucagon
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 2
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Evidence read
15.6% in MOMENTUM
Pemvidutide should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as 15.6%, tied to MOMENTUM. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next listed milestone is 2026. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Latest FormBlends pipeline read
Trial program
MOMENTUM
Weight loss signal
15.6%
Administration
injectable
Next milestone
2026
Focused development on the intersection of obesity and MASH (fatty liver disease). The glucagon component may provide liver-specific benefits beyond weight loss alone. MOMENTUM Phase 2 trial showed 15.6% body weight reduction at the highest dose. Also demonstrated significant improvements in liver biomarkers relevant to MASH.
Clinical evidence snapshot
What the evidence can and cannot say about Pemvidutide
Pemvidutide should be read as an evidence-tracking page, not as a patient access page. FormBlends currently tracks the main reported weight-loss signal as 15.6%, tied to MOMENTUM. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next listed milestone is 2026. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is Pemvidutide available now or watchlist only?
Pemvidutide should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- Pemvidutide
- Developer
- Altimmune
- Stage
- Phase 2
- Mechanism
- Dual agonists
Step 1
Read the stage first
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is Pemvidutide?
Pemvidutide is a phase 2 obesity or metabolic program from Altimmune built around GLP-1/Glucagon.
Is Pemvidutide approved?
No. Pemvidutide is still a Phase 2 asset. It has a real differentiated story, but it is not close enough to be treated as a current approval event.
When could it matter?
2028 or later is the realistic broad-launch frame.
What Pemvidutide is
Pemvidutide is part of the dual agonists cluster in the FormBlends obesity-pipeline map. We track it because Altimmune is using GLP-1/Glucagon as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.
What FormBlends is watching next
For Pemvidutide, the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
More dual agonists on FormBlends
Frequently asked questions
What is Pemvidutide?
Pemvidutide is a Phase 2 obesity or metabolic compound from Altimmune. FormBlends tracks it in the dual agonists group and follows it for trial progress, regulatory movement, and competitive impact.
How does Pemvidutide work?
Pemvidutide is being tracked as a GLP-1/Glucagon program. That mechanism is the main reason it sits inside the dual agonists bucket of the 2026 obesity pipeline.
Is Pemvidutide available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking Pemvidutide?
Dual agonists are still where a large share of the near-term obesity market is being shaped. This group includes both incremental challengers to today's GLP-1 leaders and some of the most commercially realistic next-wave products.